JAK3 and acute lymphoblastic leukemia: This was supported by previous preclinical data regarding its effectiveness of targeting JAK3 mutations as well as a successful therapy with tofacitinib described in a single‐patient case report with T‐ALL and a JAK3 mutation [11, 12].